Glonghui, May 11 | Bank of America: The target price of Novavax Pharmaceuticals was raised from $4 to $12, and the rating was raised from “outperforming the market” to “neutral.”
美银大幅上调诺瓦瓦克斯医药目标价至12美元
Bank of America sharply raised the target price of Novavax Pharmaceuticals to $12
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.